National Cancer Institute (NCI): all 3,554 studies

Page 30 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00059813Phase 2
• Anidulafungin Versus Fluconazole in the Treatment of CandidemiaCompletedNCT00058682Phase 3
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
• Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00058279Phase 1/2
• Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00058253Phase 1
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00058097Phase 2
• Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate CancerCompletedNCT00058084Phase 2
• BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00057850Phase 1/2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast CancerCompletedNCT00055861Phase 2
• Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsCompletedNCT00055809Phase 2
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00055757Phase 2
• Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid TumorsCompletedNCT00054548Phase 1
• Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00054535Phase 2
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
• Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent NeuroblastomaTerminatedNCT00054405Phase 1
• Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial NeoplasiaCompletedNCT00054041Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk NeuroblastomaTerminatedNCT00053950Phase 1
• Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform NeurofibromasCompletedNCT00053937Phase 1
• Fenretinide in Treating Children With Recurrent or Resistant NeuroblastomaCompletedNCT00053326Phase 2
• Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00053183Phase 1
• Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00052949Phase 2
• SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal NeoplasiaCompletedNCT00052897Phase 1/2
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
• Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast CancerCompletedNCT00052728Phase 2
• Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00052689Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal CancerTerminatedNCT00052585Phase 2
• Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal CancerCompletedNCT00052559Phase 1
• Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
• Oxaliplatin in Treating Patients With Liver CancerCompletedNCT00052364Phase 2
• Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast CancerCompletedNCT00052351Phase 2
• Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00052338Phase 1
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00049569Not applicable
• Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
• Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00049387Phase 1
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat CancerCompletedNCT00049166Phase 1
• Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast CancerCompletedNCT00049114Phase 2
• Bortezomib and Docetaxel in Treating Patients With Advanced Solid TumorsTerminatedNCT00049088Phase 1
• Phase I Study of HeFi-1 to Treat Cancers With CD30 ProteinCompletedNCT00048880Phase 1
• Depsipeptide to Treat Thyroid and Other Advanced CancersCompletedNCT00048334Phase 1
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00047307Phase 1
• Flavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00047203Phase 2
• Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00047190Phase 2
• Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00047047Phase 1
• E7389 in Treating Patients With Advanced Solid TumorsCompletedNCT00047034Phase 1
• Combination Chemotherapy in Treating Patients With Advanced Solid TumorsCompletedNCT00046917Phase 1
• Cancer Risk in Carriers of the Gene for Xeroderma PigmentosumCompletedNCT00046189
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT00045565Phase 1
• Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerCompletedNCT00045526Phase 2
• UCN-01 and Prednisone in Treating Patients With Solid Tumors or LymphomaCompletedNCT00045500Phase 1
• Brachytherapy in Treating Patients With Recurrent Malignant GliomaCompletedNCT00045474Phase 1
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate CancerCompletedNCT00045331Not applicable
• Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate CancerCompletedNCT00045227Phase 2
• Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT00045201Phase 1
• Imatinib Mesylate in Treating Patients With Metastatic Breast CancerCompletedNCT00045188Phase 2
• Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00045097Phase 2
• Collection of Blood, Bone Marrow, Tumor or Tissue SamplesCompletedNCT00043615
• Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic RiskCompletedNCT00043472
• Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By SurgeryCompletedNCT00043121Phase 1
• Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal NeoplasiaCompletedNCT00043043Phase 2
• Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00042978Phase 2
• Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTerminatedNCT00042952Phase 2
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00042874Phase 1
• UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00042861Phase 1
• Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung CancerTerminatedNCT00042835Phase 1
• Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00042809Phase 1
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
• Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerCompletedNCT00041340Phase 2
• Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder CancerCompletedNCT00041106Phase 2
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00041041Phase 2
• Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerCompletedNCT00040794Phase 2
• Gefitinib in Treating Children With Refractory Solid TumorsCompletedNCT00040781Phase 1
• Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00040768Phase 2
• BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00040755Phase 2
• Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171CCompletedNCT00040729
• Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompletedNCT00040222
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate CancerCompletedNCT00039624Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerCompletedNCT00039611Not applicable
• Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
• Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid TumorsCompletedNCT00039481Phase 1
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
• Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
• UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic CancerCompletedNCT00039403Phase 1
• Gefitinib and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00039390Phase 1
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2

← National Cancer Institute (NCI) overview and focus areas